He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

By Ella Käck

January 22, 2025 11:06 AM

The board of Karolinska Development has appointed Ben Toogood, a board member since 2021, as chairman until the next annual general meeting, according to a press release

Ben Toogood, the CEO of the pharmaceutical company Invox, brings over 25 years of experience in the pharmaceutical industry, having worked at companies such as Novartis and Aspen Pharmacare.

He succeeds Professor Hans Wigzell, who stepped down from the position at his own request, as announced on December 11.

No specific reason has been given for Wigzell's decision to resign. He has served multiple terms as Chairman since the company’s founding.

The announcement came shortly after Karolinska Development revealed a cost-saving program aimed at reducing personnel expenses by 20 percent, as previously reported by Life Science Sweden tidigare rapporterat.

Karolinska Development, founded in 2003, is an investment company focused on developing medical innovations from research conducted at the Karolinska Institute and other nordic universities. The company’s portfolio currently includes eleven companies involved in pharmaceutical development.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.